AstraZeneca PLC (AZN) Forms $36.41 Double Top; Last Week Coca-Cola European Partners plc (CCE) Coverage

AstraZeneca PLC (NYSE:AZN) Logo

AstraZeneca PLC (AZN) formed double top with $38.60 target or 6.00% above today’s $36.41 share price. AstraZeneca PLC (AZN) has $90.68 billion valuation. The stock increased 0.48% or $0.1741 during the last trading session, reaching $36.4141. About 1.36M shares traded. AstraZeneca PLC (NYSE:AZN) has risen 9.03% since May 16, 2017 and is uptrending. It has underperformed by 2.52% the S&P500.

Among 25 analysts covering Coca-Cola Enterprises Inc. (NYSE:CCE), 11 have Buy rating, 3 Sell and 11 Hold. Therefore 44% are positive. Coca-Cola Enterprises Inc. had 66 analyst reports since August 3, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Thursday, December 17 by UBS. The stock of Coca-Cola European Partners plc (NYSE:CCE) has “Hold” rating given on Friday, May 5 by Susquehanna. The stock has “Neutral” rating by UBS on Friday, July 31. The stock of Coca-Cola European Partners plc (NYSE:CCE) has “Neutral” rating given on Thursday, September 15 by Credit Suisse. Susquehanna downgraded the shares of CCE in report on Monday, November 13 to “Negative” rating. Jefferies maintained the stock with “Hold” rating in Friday, July 14 report. As per Tuesday, September 1, the company rating was downgraded by Zacks. Jefferies maintained the shares of CCE in report on Wednesday, April 26 with “Hold” rating. The stock has “Hold” rating by Stifel Nicolaus on Tuesday, December 6. On Thursday, August 10 the stock rating was maintained by Susquehanna with “Hold”. See Coca-Cola European Partners plc (NYSE:CCE) latest ratings:

26/04/2018 Broker: Jefferies Rating: Hold
23/04/2018 Broker: Susquehanna Rating: Sell New Target: $33.0000 Maintain
17/04/2018 Broker: Goldman Sachs Rating: Buy Upgrade
26/03/2018 Broker: Morgan Stanley Rating: Overweight Initiates Coverage On
16/02/2018 Broker: Deutsche Bank Old Rating: Buy New Rating: Buy Old Target: $43 New Target: $46 Maintain
12/02/2018 Broker: Susquehanna Rating: Sell New Target: $30.0 Maintain
05/01/2018 Broker: Macquarie Research Rating: Hold New Target: $40.0 Downgrade
14/12/2017 Broker: Deutsche Bank Rating: Buy New Target: $43 Initiates Coverage On

Analysts await AstraZeneca PLC (NYSE:AZN) to report earnings on May, 18 before the open. They expect $0.28 EPS, down 71.72% or $0.71 from last year’s $0.99 per share. AZN’s profit will be $697.23 million for 32.51 P/E if the $0.28 EPS becomes a reality. After $1.30 actual EPS reported by AstraZeneca PLC for the previous quarter, Wall Street now forecasts -78.46% negative EPS growth.

Among 26 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 17 have Buy rating, 0 Sell and 9 Hold. Therefore 65% are positive. AstraZeneca plc (ADR) has $50 highest and $32 lowest target. $40.14’s average target is 10.23% above currents $36.4141 stock price. AstraZeneca plc (ADR) had 45 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of AstraZeneca PLC (NYSE:AZN) earned “Overweight” rating by JP Morgan on Friday, December 29. The rating was upgraded by Credit Suisse on Friday, May 12 to “Neutral”. HSBC upgraded AstraZeneca PLC (NYSE:AZN) on Wednesday, September 2 to “Buy” rating. Deutsche Bank upgraded the shares of AZN in report on Monday, September 14 to “Buy” rating. Leerink Swann maintained the shares of AZN in report on Monday, October 23 with “Market Perform” rating. The company was downgraded on Thursday, July 27 by Leerink Swann. Credit Suisse downgraded the stock to “Underperform” rating in Tuesday, October 20 report. The stock of AstraZeneca PLC (NYSE:AZN) earned “Outperform” rating by Bernstein on Friday, September 22. The stock of AstraZeneca PLC (NYSE:AZN) has “Top Pick” rating given on Tuesday, January 26 by Oddo & Cie. The stock of AstraZeneca PLC (NYSE:AZN) has “Market Perform” rating given on Monday, May 2 by Leerink Swann.

Investors sentiment decreased to 0.5 in 2017 Q4. Its down 0.50, from 1 in 2017Q3. It dived, as 1 investors sold Coca-Cola European Partners plc shares while 1 reduced holdings. 0 funds opened positions while 1 raised stakes. 53,464 shares or 8.98% less from 58,740 shares in 2017Q3 were reported. Moreover, Green Square Capital Ltd Co has 0.15% invested in Coca-Cola European Partners plc (NYSE:CCE) for 25,324 shares. 1,140 were accumulated by Focused Wealth. Ar Asset Mngmt Incorporated accumulated 27,000 shares or 0.41% of the stock.

More recent Coca-Cola European Partners plc (NYSE:CCE) news were published by: Streetinsider.com which released: “Glenview Capital Enters AmerisourceBergen (ABC), Express Scripts (ESRX), T-Mobile (TMUS) (more…) -13F” on May 15, 2018. Also Globenewswire.com published the news titled: “Recent Analysis Shows Ares Capital, The Middleby, Cardtronics, NOW, Coca-Cola European Partners, and News …” on May 11, 2018. Benzinga.com‘s news article titled: “Molson Coors Downgraded By Goldman Sachs On Weak Volume; Coca-Cola European Partners Upgraded On Growth …” with publication date: April 17, 2018 was also an interesting one.

Coca-Cola European Partners plc, together with its subsidiaries, produces, distributes, and sells a range of non-alcoholic ready-to-drink beverages. The company has market cap of $18.43 billion. It offers drinks primarily under the Coca-Cola, Diet Coke/Coca-Cola Light, Coke Zero, Coca-Cola Life, Fanta, and Sprite brands. It has a 22.67 P/E ratio. The firm also provides energy drinks, waters, juices, sports drinks and ready-to-drink teas.

AstraZeneca PLC (NYSE:AZN) Ratings Chart